P&F Products & Features GmbH Expands Its Portfolio with AVVie GmbH Acquisition

P&F Products & Features GmbH Welcomes AVVie GmbH

P&F Products & Features GmbH, based in Vienna, Austria, proudly announces its recent acquisition of AVVie GmbH. Founded by the esteemed cardiac surgeon Professor Werner Mohl, AVVie has been instrumental in developing advanced technologies aimed at structural heart repair, primarily through its innovative AngelValve™ system.

The AngelValve™ is a groundbreaking transcatheter solution designed to address the critical unmet needs in treating mitral valve disease, particularly among patients who presently have limited or no treatment options. With over 13 million people suffering from mitral regurgitation across Europe and the United States, this acquisition is a strategic move to tackle a significant healthcare challenge.

Current statistics reveal that only about 5% of patients with moderate to severe mitral valve disease receive appropriate treatment. Closing this treatment gap and enhancing the quality of life for millions is central to P&F's mission. By integrating AVVie’s research and development capabilities and intellectual property with P&F's extensive global reach in product development, clinical affairs, regulatory processes, manufacturing, and marketing, the company is well-positioned to accelerate innovation and streamline product development timelines.

Katharina Kiss, MD, CEO of P&F, emphasized, “This acquisition underscores our unwavering commitment to advancing innovative therapies for structural heart diseases. By leveraging AVVie’s engineering excellence alongside P&F’s clinical trial acumen and regulatory expertise, we are poised to propel the AngelValve™ platform forward and deliver substantial innovations for healthcare providers and patients globally.”

Siegfried Einhellig, COO and President of R&D at P&F, added, “The combination of exceptional engineering talent and proven development capabilities is immensely exciting. We look forward to transforming this innovation into a successful therapy.”

Although the financial details of the transaction were not disclosed, this acquisition marks a significant step in P&F’s journey towards becoming a global leader in structural heart therapy.

P&F Products & Features GmbH operates in approximately 70 countries, mastering cardiovascular innovation with over 25 years of experience. The company continues to produce cutting-edge solutions in Europe, Asia, and Brazil. To learn more about P&F's innovative offerings, visit productsandfeatures.com.

In summary, the acquisition of AVVie not only symbolizes P&F's growth strategy but also its dedication to fulfilling critical medical needs in cardiology, potentially transforming the landscape of treatment for mitral valve disease patients worldwide.